| 1 |
A Phase 1 Combination Study of 177Lu Pocuvotide Satetraxetan and Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| RPT |
mCRPC |
PSMA & PD-1 |
Phase 1 |
Cellbion Co., Ltd. |
RS-2026-25502433 |
|
| 2 |
A Phase I study of GM103 administered via intratumoral injection in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors. |
| Gene & Nucleic acids |
Ovarian Cancer, Breast Cancer (TNBC) |
Locally advanced, unresectable, refractory and/or metastatic solid tumors |
Phase 1 |
GeneMedicine Co., Ltd. |
RS-2026-25501678 |
|
| 3 |
CK1α-Selective Molecular Glue Degrader for Solid Tumors |
| TPD |
Solid tumors |
CK1α |
Phase 1 |
Pin Therapeutics |
RS-2026-25501524 |
|
| 4 |
Clinical Development of the Oral BTK Degrader UBX-303061 for Relapsed/Refractory B-Cell Malignancies |
| TPD |
Relapsed/Refractory B-cell Malignancies |
BTK/HCK/LYN |
Phase 1 |
Ubix Therapeutics, Inc. |
RS-2025-25454729 |
|
| 5 |
Clinical Phase 1 Development of BVAC-E6E7 for HPV16 and/or HPV18 Positive Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Cell therapies |
HPV16/18 positive HNSCC |
HPV16/18 E6, E7 protein |
Phase 1 |
Cellid |
RS-2025-25451121 |
|
| 6 |
Clinical research for the development of MASTL inhibitors as a new anti-cancer drug |
| Small molecules |
CRC, GC,Sarcoma, TNBC, AML etc. |
MASTL |
Phase 1 |
Avelos Therapeutics, Inc. |
RS-2025-25446915 |
|
| 7 |
Development of the novel HER2 TKI YH42946 for Solid Tumors |
| Small molecules |
NSCLC |
HER2 |
Phase 1 |
YUHAN |
RS-2025-02213533 |
|
| 8 |
Phase 1 clinical trial for trans-splicing ribozyme-based RNA editing therapeutics for glioblastoma |
| Gene & Nucleic acids |
GBM |
hTERT mRNA |
Phase 1 |
Rznomics Inc. |
RS-2025-02213273 |
|
| 9 |
Clinical Development of Next-Generation EGFR Mutant Non-Small Cell Lung Cancer Treatment, JIN-A02 |
| Small molecules |
NSCLC |
EGFR |
Phase 1 |
J INTS BIO |
RS-2025-02183074 |
|
| 10 |
Global Phase 1 Clinical Development of SNB-101, a Novel Therapeutic for Small Cell Lung Cancer |
| Small molecules |
SCLC |
Topoisomerase 1 |
Phase 1 |
SN BioScience Inc. |
RS-2025-02073050 |
|
| 11 |
Development of CD5 CAR-NK therapeutics for treating NK and T-cell malignancies |
| Cell therapies |
NK and T-cell malignancies |
CD5 |
Phase 1 |
GC Cell |
RS-2024-00508039 |
|
| 12 |
Clinical phase I development for SCLC and GIST using antibodydrug conjugate targeting c-Kit |
| Antibody |
SCLC, GIST |
c-Kit |
Phase 1 |
Novelty Nobility Inc. |
RS-2024-00461295 |
|
| 13 |
DM5167 Phase 1 Clinical Trial of a 2nd Generation PARP-1 Selective Inhibitor |
| Small molecules |
Solid cancer |
PARP-1 |
Phase 1 |
Digmbio |
RS-2024-00460284 |
|
| 14 |
|
| rProtein |
Metastatic Melanoma |
CTLA-4/PD-L1, IL-2R |
Phase 1 |
GI Innovation |
RS-2024-00459844 |
|
| 15 |
Phase 1 clinical study of FB849, HPK1 inhibitor as a nextgeneration immuno-oncology therapy |
| Small molecules |
Ovarian cancer, Endometrial cancer, Renal cell carcinoma |
HPK1 |
Phase 1 |
1ST Biotherapeutics, Inc. |
RS-2024-00332279 |
|
| 16 |
Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma |
| Cell therapies |
Liver cancer |
GPC3 |
Phase 1 |
Eutilex Co.,Ltd. |
RS-2023-00283610 |
|
| 17 |
Phase 1 clinical Study of ENPP1 inhibitory Immunotherapy TXN10128 |
| Small molecules |
Solid tumor |
ENPP1 |
Phase 1 |
Txinno Bioscience Inc. |
RS-2023-00282830 |
|
| 18 |
TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients |
| Cell therapies |
B cell lymphoma |
CD19 |
Phase 1 |
TICAROS |
RS-2023-00258721 |
|
| 19 |
Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor |
| Small molecules |
Colorectal cancer |
mutant RON |
Phase 1 |
Wellmarkerbio Co., Ltd. |
RS-2023-00219060 |
|
| 20 |
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors |
| Small molecules |
Solid Tumor |
TGFβR1 |
Phase 1 |
Tium BIO |
RS-2022-00167091 |
|
| 21 |
Clinical Phase 1 Development of SKL27969, a Novel Brain Penetrating PRMT5 Inhibitor |
| Small molecules |
Glioblastoma |
PRMT5 |
Phase 1 |
SK Biopharmaceuticals |
RS-2022-00165541 |
|
| 22 |
YYB-103 |
| Cell therapies |
Glioblastoma |
IL13Rα2 |
Phase 1 |
CellabMED |
HN22C0592 |
|
| 23 |
A Phase 1/2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib or local radiotherapy in patients with advanced or metastatic solid tumors (Keynote B59) |
| rProtein |
Advanced or Metastatic Solid Tumor |
CD80, IL-2 |
Phase 1 |
GI Innovation, Inc. |
HN22C0451 |
|
| 24 |
Phase I clinical study of innovative CD19-targeted CAR-T |
| Cell therapies |
Non-Hodgkin Lymphoma |
CD19 |
Phase 1 |
AbClon Inc. |
HN22C0009 |
|
| 25 |
Completion of YBL-006 phase I trial;
a novel immune checkpoint inhibitor |
| Antibody |
Squamous cell carcinoma, Renal cell carcinoma |
PD-1 |
Phase 1 |
Y-Biologics |
HN21C1391 |
|
| 26 |
Clinical development of PSMA target therapeutic radiopharmaceutical for prostate cancer |
| RPT |
Prostate cancer |
PSMA |
Phase 1 |
FutureChem. Co., Ltd. |
HN21C1297 |
|
| 27 |
Phase 1 clinical development of anti-cancer bispecific antibody ABL501 targeting LAG-3 and PD-L1 |
| Antibody |
NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, Triple-Negative Breast Cancer, Ovarian cancer |
PD-L1, LAG-3 |
Phase 1 |
ABL Bio |
HN21C0979 |
|
| 28 |
PhaseⅠclinical development of the 4th generation NSCLC-TKI BBT-176, which targets C797S-harboring EGFR mutations |
| Small molecules |
NSCLC |
EGFR(C797S) |
Phase 1 |
Bridge Biotherapeutics, Inc. |
HN21C0859 |
|
| 29 |
Clinical trial and drug approval of the next generation CD19 CAR-T designed to overcome immune-suppressive environment |
| Cell therapies |
Non-small cell lymphoma |
CD19 |
Phase 1 |
Curocell Inc. |
HN21C0653 |
|
| 30 |
Phase 1 clinical trial of CKD-702, bispecific antibody, in NSCLC |
| Antibody |
NSCLC |
c-MET, EGFR |
Phase 1 |
Chong Kun Dang pharmaceutical Corp. |
HN21C0551 |
|